Craif's Urinary Cancer Test 'miSignal Scan' Introduced at JA Kanagawa Prefectural Welfare Federation Health and Welfare Centers
Bio-AI startup Craif announces the introduction of its urinary cancer test 'miSignal Scan' at JA Kanagawa Health Centers, enabling non-invasive early cancer detection for local residents.
📋 Article Processing Timeline
- 📰 Published: April 10, 2026 at 19:00
- 🔍 Collected: April 11, 2026 at 00:28 (5h 28m after Published)
- 🤖 AI Analyzed: April 20, 2026 at 00:14 (215h 46m after Collected)
Bio-AI startup Craif Inc. (Location: Shinjuku-ku, Tokyo, CEO: Ryuichi Onose, hereinafter Craif) announces that its urinary cancer test 'miSignal Scan' will be newly introduced at JA Kanagawa Prefectural Welfare Federation Health and Welfare Centers (JA Health Management Center Atsugi, JA Health Management Center Sagamihara). With this introduction, an environment will be established where JA union members and local residents in Kanagawa Prefecture can undergo cancer risk screening based on cutting-edge urinary microRNA analysis technology, raising expectations for cancer prevention and early detection.
About 'miSignal Scan'
'miSignal Scan' is a test that extracts microRNA from urine and analyzes it with AI to evaluate the risk of 10 types of cancer*, including pancreatic cancer, by cancer type from Stage 1. By simply collecting urine, testing can be performed without physical burden.
For details, please visit the website.
https://misignal.jp/
'miSignal Scan' is not a medical device. It determines risk by statistically calculating the analyzed information, and does not replace 'diagnosis' of whether one is suffering from cancer as a medical practice. Even if determined to be low risk, it does not guarantee the absence of cancer or that one will not develop cancer in the future.
* Ovarian cancer and breast cancer are applicable for women only, and prostate cancer is applicable for men only.
About Craif
Craif is a bio-AI startup founded in 2018 working on early cancer detection. Fusing its proprietary analysis technology platform 'NANO IP®︎ (NANO Intelligence Platform)'—which detects diverse biomarkers such as DNA and microRNA with high precision from body fluids including urine—with AI technology, the company is developing innovative tests that enable ultra-early detection, early treatment, and early return from cancer. By widely delivering the power of biotechnology and AI to society, we promote our vision of 'realizing a society where people fulfill their natural lifespans.'
[Company Profile]
Company Name: Craif Inc.
Representative: Representative Director Ryuichi Onose
Established: 2018
About 'miSignal Scan'
'miSignal Scan' is a test that extracts microRNA from urine and analyzes it with AI to evaluate the risk of 10 types of cancer*, including pancreatic cancer, by cancer type from Stage 1. By simply collecting urine, testing can be performed without physical burden.
For details, please visit the website.
https://misignal.jp/
'miSignal Scan' is not a medical device. It determines risk by statistically calculating the analyzed information, and does not replace 'diagnosis' of whether one is suffering from cancer as a medical practice. Even if determined to be low risk, it does not guarantee the absence of cancer or that one will not develop cancer in the future.
* Ovarian cancer and breast cancer are applicable for women only, and prostate cancer is applicable for men only.
About Craif
Craif is a bio-AI startup founded in 2018 working on early cancer detection. Fusing its proprietary analysis technology platform 'NANO IP®︎ (NANO Intelligence Platform)'—which detects diverse biomarkers such as DNA and microRNA with high precision from body fluids including urine—with AI technology, the company is developing innovative tests that enable ultra-early detection, early treatment, and early return from cancer. By widely delivering the power of biotechnology and AI to society, we promote our vision of 'realizing a society where people fulfill their natural lifespans.'
[Company Profile]
Company Name: Craif Inc.
Representative: Representative Director Ryuichi Onose
Established: 2018